title: [2013: The Seville document on consensus on the alternatives to allogenic blood transfusion. Update to the Seville document. Spanish Societies of Anaesthesiology (SEDAR), Haematology and Haemotherapy (SEHH), Hospital Pharmacy (SEFH), Critical Care Medicine (SEMICYUC), Thrombosis and Haemostasis (SETH) and Blood Transfusion (SETS)].
abstract: As allogeneic blood transfusion (ABT) is not harmless, multiple alternatives to TSA (AABT) have emerged, but there is a huge variability with respect to their indications and appropriate use. This variability results from the interplay of a number of factors, which include physicians specialty, knowledge and preferences, degree of anaemia, transfusion policy, and AABT availability. Since the ABBT are not harmless and may not meet costeffectiveness criteria, such avariability is unacceptable. The Spanish Societies of Anaesthesiology (SEDAR), Haematology and Haemotherapy (SEHH), Hospital Pharmacy (SEFH), Critical Care Medicine (SEMICYUC), Thrombosis and Haemostasis (SETH) and Blood Transfusion (SETS) have developed a Consensus Document for the proper use of AABTs. A panel of experts convened by these six Societies have conducted a systematic review of the medical literature and developed the «2013. Seville Document of Consensus on Alternatives to Allogeneic Blood Transfusion», which only considers those AABT aimed to decrease the transfusion of packed red cells. The AABTs are defined as any pharmacological and non-pharmacological measure aimed to decrease the transfusion of of red blood cell concentrates, while preserving the patient safety. For each AABT, the main question is formulated, positively or negatively, as: «Does or does not this particular AABT reduce the transfusion rate?» All the recommendations on the use of AABTs were formulated according to the GRADE (Grades of Recommendation Assessment, Development and Evaluation) methodology.
authors.forename: S R
authors.initials: SR
authors.lastname: Leal-Noval
authors.forename: M
authors.initials: M
authors.lastname: Muñoz
authors.forename: M
authors.initials: M
authors.lastname: Asuero
authors.forename: E
authors.initials: E
authors.lastname: Contreras
authors.forename: J A
authors.initials: JA
authors.lastname: García-Erce
authors.forename: J V
authors.initials: JV
authors.lastname: Llau
authors.forename: V
authors.initials: V
authors.lastname: Moral
authors.forename: J A
authors.initials: JA
authors.lastname: Páramo
authors.forename: M
authors.initials: M
authors.lastname: Quintana
mesh_terms: D016063:Blood Loss, Surgical; D001802:Blood Substitutes / Q000009:adverse effects / Q000627:therapeutic use; D057668:Bloodless Medical and Surgical Procedures / Q000009:adverse effects / Q000592:standards*; D017707:Erythrocyte Transfusion / Q000009:adverse effects; D006801:Humans; D057725:Operative Blood Salvage / Q000592:standards; D013916:Thrombelastography; D065227:Transfusion Reaction
chemical_list: D001802:Blood Substitutes